NASDAQ:CRDF Cardiff Oncology Q3 2026 Earnings Results & Report $0.85 0.00 (-0.15%) Closing price 04:00 PM EasternExtended Trading$0.83 -0.02 (-2.41%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cardiff Oncology beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.12 versus the -$0.1380 consensus estimate, while revenue of $171 thousand topped the $81 thousand estimate by $90.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Cardiff Oncology EPS ResultsActual EPS-$0.12Consensus EPS -$0.1380Beat/MissBeat by +$0.0180One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCardiff Oncology Revenue ResultsActual Revenue$171 thousandExpected Revenue$81 thousandBeat/MissBeat by +$90.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cardiff Oncology Q3 2026 Earnings FAQ Did Cardiff Oncology beat earnings estimates for Q3 2026? Cardiff Oncology (NASDAQ:CRDF) reported earnings of -$0.12 per share for Q3 2026, beating the consensus estimate of -$0.1380. The report was announced on Thursday, November 12, 2026. What was Cardiff Oncology's revenue for Q3 2026? Cardiff Oncology reported revenue of $171 thousand for Q3 2026, against a consensus estimate of $81 thousand. Cardiff Oncology Earnings HeadlinesTranscript : Cardiff Oncology, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 02:40 PMNovember 16 at 1:43 PM | marketscreener.comMCardiff Oncology, Inc. (CRDF) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 16 at 1:43 PM | seekingalpha.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 17 at 1:00 AM | Base Camp Trading (Ad)Cardiff: FDA Grants Fast Track Designation To OnvansertibNovember 16 at 8:42 AM | rttnews.comCardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal CancerNovember 16 at 7:00 AM | globenewswire.comCardiff Oncology Reports Third Quarter 2026 Results and Provides Business UpdateNovember 12, 2026 | globenewswire.comSee More Cardiff Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email. Email Address About Cardiff OncologyCardiff Oncology (NASDAQ:CRDF) is a clinical-stage biotechnology company focused on developing cancer treatments. Its lead drug candidate, onvansertib, is an oral, selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division that the company is investigating as a target in cancer therapy. The company is studying onvansertib in combination with existing treatments for several cancers, including metastatic colorectal cancer and acute myeloid leukemia. These programs remain in clinical development, and the candidate is not an approved treatment. Based in San Diego, California, Cardiff Oncology was formerly known as Trovagene, Inc. The company adopted its current name in 2020. Mark Erlander serves as its chief executive officer.View Cardiff Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.